The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Roytman A.P.
Russian Medical Academy for Continuous Professional Education
Kuznetsova T.E.
Russian Medical Academy for Continuous Professional Education;
Sklifosovsky Research Institute for Emergency Medicine
Bugrov A.V.
Russian Medical Academy for Continuous Professional Education
Dolgov V.V.
Russian Medical Academy for Continuous Professional Education
Godkov M.A.
Russian Medical Academy for Continuous Professional Education;
Sklifosovsky Research Institute for Emergency Medicine
Laboratory biomarkers for the prognosis of chronic heart failure
Journal: Laboratory Service. 2024;13(3): 5‑16
Views: 514
Downloaded: 1
To cite this article:
Roytman AP, Kuznetsova TE, Belyaev IA, Bugrov AV, Tazina SYa, Dolgov VV, Godkov MA. Laboratory biomarkers for the prognosis of chronic heart failure. Laboratory Service.
2024;13(3):5‑16. (In Russ.)
https://doi.org/10.17116/labs2024130315
Chronic heart failure (CHF) is a pressing worldwide medical problem, in our country in particular. The incidence of CHF is constantly increasing. The epidemiological forecast shows that by 2050, the number of patients with CHF will increase by 60% compared to 2010. According to the latest data, the total number of patients with CHF in Russia is 12 million, 4.5 million of whom have III and IV New York Heart Association (NYHA) functional class. Heart transplantation is a high-tech method of treating terminal heart failure and is recognized as the gold standard of care for patients whose risk of death within a year is more than 50% if it is impossible to use other methods of treatment. A number of new laboratory biomarkers can help predict adverse outcomes in patients with CHF.
To summarize information about laboratory biomarkers for the assessment and prognosis of CHF and explaine the actuality of their further study in clinical practice.
This review is based on articles over the past 10 years conducted using the resources of the PubMed and eLIBRARY research engines using keywords.
Existing laboratory markers used to assess and predict the course of CHF have a number of limits. The comparison of biomarkers made including diagnostic characteristics, the advantages and disadvantages of using biomarkers in clinical practice.
It is efficient to use several laboratory biomarkers to assess and predict the course of CHF. The most promising laboratory biomarkers for the assessment and prognosis of CHF are neprilysin, fractalkine, interleukin-6 and biomarkers of of extracellular matrix metabolism (MMP-2, MMP-8, PIIINP and TIMP-1).
Authors:
Roytman A.P.
Russian Medical Academy for Continuous Professional Education
Kuznetsova T.E.
Russian Medical Academy for Continuous Professional Education;
Sklifosovsky Research Institute for Emergency Medicine
Bugrov A.V.
Russian Medical Academy for Continuous Professional Education
Dolgov V.V.
Russian Medical Academy for Continuous Professional Education
Godkov M.A.
Russian Medical Academy for Continuous Professional Education;
Sklifosovsky Research Institute for Emergency Medicine
Received:
09.07.2024
Accepted:
08.10.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.